Whereas no difference in PFS at any side was observed in the FOXFIRE Combined Analysis (HR: 0.90 [95% CI: 0.79-1.02] p= 0.108), the risk of first progression in the liver as per competing risk analysis remained significantly lower for patients receiving SIR-Spheres® Y-90 resin microspheres, as previously shown also in the SIRFLOX study.
Adapted from Wasan HS et al. Lancet Oncol 2017; 18: 1159-71
Wasan HS et al. Lancet Oncol 2017; 18: 1159-71.